Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of NNC6019-0001 in transthyretin amyloid cardiomyopathy
NL-OMON51443Phase 2Recruiting
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), familial amyloid cardiomyopathy (FAC) and wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) (3 arms), sponsored by Novo Nordisk. Primary endpoints: Change in 6-minute walk test and Change in NT-proBNP. Started Nov 2023; status: recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)familial amyloid cardiomyopathy (FAC)wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)
Beyond the preview
Go deeper on NL-OMON51443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51443.